- Home
- A-Z Publications
- Current Alzheimer Research
- Previous Issues
- Volume 15, Issue 4, 2018
Current Alzheimer Research - Volume 15, Issue 4, 2018
Volume 15, Issue 4, 2018
-
-
Lipid Biomarkers in Alzheimer's Disease
Background: There are now significant evidences that lipid metabolism is affected in numerous neurodegenerative diseases including Alzheimer’s disease. These dysfunctions lead to abnormal levels of certain lipids in the brain, cerebrospinal fluid and plasma. It is consequently of interest to establish lipid profiles in neurodegenerative diseases. This approach, which can contribute to identify lipid biomarkers of Alzheimers' dise Read More
-
-
-
The Involvement of Post-Translational Modifications in Alzheimer's Disease
Background: Alzheimer's disease (AD) is a neurodegenerative disorder recognized as the most common cause of chronic dementia among the ageing population. AD is histopathologically characterized by progressive loss of neurons and deposits of insoluble proteins, primarily composed of amyloid-β pelaques and neurofibrillary tangles (NFTs). Methods: Several molecular processes contribute to the formation of AD cellular h Read More
-
-
-
PPARs in Neurodegenerative and Neuroinflammatory Pathways
Authors: E. Benedetti, L. Cristiano, A. Antonosante, M. d'Angelo, B. D'Angelo, S. Selli, V. Castelli, R. Ippoliti, A. Giordano and A. CiminiBackground: PPARs are lipid sensors activated by dietary lipids or their metabolites, mainly fatty acids and eicosanoids, that play critical roles in CNS biology, since brain has a very high lipid content and has the higher energetic metabolism in the body. Methods: In neurodegenerative diseases in addition to metabolic impairment, also neuroinflammation is observed and PPARs are also closely linked to inflammatory processes. S Read More
-
-
-
Targeting PPARalpha in Alzheimer's Disease
Authors: Barbara D'Orio, Anna Fracassi, Maria P. Ceru and Sandra MorenoBackground: The molecular mechanisms underlying Alzheimer's disease (AD) are yet to be fully elucidated. The so-called “amyloid cascade hypothesis” has long been the prevailing paradigm for causation of disease, and is today being revisited in relation to other pathogenic pathways, such as oxidative stress, neuroinflammation and energy dysmetabolism. The peroxisome proliferator-activated receptors (PPARs) are ex Read More
-
-
-
The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer's Disease
More LessBackground: During aging and in age-associated disorders, such as Alzheimer's Disease (AD), learning abilities decline. Probably, disturbances in signal transduction in brain cells underlie the cognitive decline. The phosphorylation/dephosphorylation imbalance occurring in degenerating neurons was recently related to abnormal activity of one or more signal transduction pathways. AD is known to be associated with alter Read More
-
-
-
Modulation of Inflammation as a Way of Delaying Alzheimer's Disease Progression: The Diet's Role
Authors: R. Businaro, M. Corsi, R. Asprino, C. Di Lorenzo, D. Laskin, R.M. Corbo, S. Ricci and A. PintoBackground: Most of the recent reports suggest that inflammatory mediators play a central role in the etiopathogenesis of Alzheimer's disease (AD) and that the conditions leading to a chronic low-grade inflammation, such as stress, depression, obesity and metabolic syndrome, increase the odds of developing Mild Cognitive Impairment (MCI) and AD. Microglia cells are the main actors in the AD process: stimuli from the micr Read More
-
-
-
Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Background: Although it is known that Alzheimer's disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in hu Read More
-
-
-
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Background: While the angiotensin-converting enzyme degrades amyloid-β, angiotensinconverting enzyme inhibitors (ACEis) may slow cognitive decline by way of cholinergic effects, by increasing brain substance P and boosting the activity of neprilysin, and by modulating glucose homeostasis and augmenting the secretion of adipokines to enhance insulin sensitivity in patients with Alzheimer’s disease dementia (A Read More
-
Volumes & issues
-
Volume 21 (2024)
-
Volume 20 (2023)
-
Volume 19 (2022)
-
Volume 18 (2021)
-
Volume 17 (2020)
-
Volume 16 (2019)
-
Volume 15 (2018)
-
Volume 14 (2017)
-
Volume 13 (2016)
-
Volume 12 (2015)
-
Volume 11 (2014)
-
Volume 10 (2013)
-
Volume 9 (2012)
-
Volume 8 (2011)
-
Volume 7 (2010)
-
Volume 6 (2009)
-
Volume 5 (2008)
-
Volume 4 (2007)
-
Volume 3 (2006)
-
Volume 2 (2005)
-
Volume 1 (2004)
Most Read This Month
Article
content/journals/car
Journal
10
5
false
en

Most Cited Most Cited RSS feed
-
-
Cognitive Reserve in Aging
Authors: A. M. Tucker and Y. Stern
-
- More Less